Covid-19 Background {#sec0001}
===================

At the end of 2019, in the city of Wuhan, the Chinese health authorities reported the first cases of a potentially fatal disease in humans, characterized by severe pneumonia and acute respiratory failure due to a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-Cov2) [@bib0001]. Corona-virus Disease 2019 (Covid-19) subsequently spread rapidly worldwide and has now become a global pandemic, providing one of the biggest challenges for critical care medicine [@bib0001]. According to the World Health Organization (WHO) in May 2020 there were 5.5m cases worldwide and approximately 350,000 deaths [@bib0002]. The estimated case fatality rate in China was 2.3%, while it was 7.2% in Italy. Mortality has been much higher in those patients older than 80 years (20.2% in Italy and 14.8% in China), particularly in those with pre-illness comorbidities such as diabetes mellitus, cardiovascular disease, obesity, cancer, and chronic respiratory disease [@bib0003]. Moreover, Covid-19 appears to be deadlier in men, with a fatality rate of 2.8% in Chinese men compared to 1.7% in women. To date, there is no specific antiviral treatment against SARS-Cov2, and new strategies are urgently needed [@bib0003].

The Inflammatory response {#sec0002}
=========================

Although current knowledge about the immune response to Covid-19 is limited, recent evidence after histopathological examinations of lung tissues have found severe alveolar epithelial damage with nonspecific innate immune response, swelling, hyperplasia, and necrosis [@bib0004]. Acute respiratory distress syndrome (ARDS) is a sepsis-related process fuelled by a cytokine storm, which is triggered by a viral infection. Excessive lung parenchyma inflammation is responsible for severe, life-threatening hypoxemia requiring mechanical ventilation and prolonged stay in the intensive care unit (ICU) and hospital [@bib0005]. Both respiratory failure phenotypes: type 1 (non ARDS or isolated viral pneumonia), and type 2 (¨true¨ ARDS or 'typical' ARDS with low pulmonary compliance) exhibit an exaggerated immune response from the cytokine storm [@bib0005]. Early diagnosis and differentiation is crucial as there are clinical implications that can determine first-line treatment.

Hypercytokinemic inflammation in Covid-19 patients, as in other viral infections shows a cytokine profile similar to the macrophage activation syndrome characterized by very high levels of proinflammatory cytokines, notably interleukins 6 (IL-6), IL-1 and IL-17, granulocyte macrophage-colony stimulating factor, and tumour necrosis factor (TNF-α) [@bib0006]. Notably, the elderly and others with comorbidities have exhibited the most aggressive inflammatory response, a phenomenon that has not so far been well understood. Unfortunately, with no specific treatment for SARS-Cov2 infection, the overall ICU mortality, in many countries, remains unacceptably high at greater than 60%, underlining the urgent need for new therapeutic strategies [@bib0007].

Selenium and Viruses {#sec0003}
====================

Reducing the incidence of severe ARDS, multiorgan failure, and new infectious complications, especially in elderly males where micronutrient deficiencies have been associated with severe adverse events during viral infections is a worthwhile aim \[[@bib0008],[@bib0009]\]. In this clinical scenario, early repletion of micronutrients such as Selenium (Se) should be a mandatory part of critical care nutrition. Specifically, we would argue that pharmaconutrition with high-dose Se, as intravenous sodium selenite, is worthy of re-investigation.

Se is an essential trace element for humans, present in selenoproteins as the 21^st^ amino acid selenocysteine [@bib0010]. The antioxidant, immunological, and anti-inflammatory properties of Se have made it one of the most extensively studied micronutrients in the critical care setting [@bib0010]. The glutathione peroxidase (GPx) family catalyses the interconversion of glutathione (GSH) and its oxidised form, glutathione disulphide (GSSG) [@bib0011]. The GSH/GSSG redox system facilitates the reduction of various hydroperoxides and oxidized forms of other antioxidants. Inadequate Se status not only compromises GPx status but also cellular and humoral immunity, which are linked to an inflammatory response involving the production of free radicals and redox control processes \[10,11\]. Reactive oxygen species (ROS) and reactive nitrogen species (RNS), including free radicals, increase expression of proinflammatory cytokines such as IL-6, and TNF-α through upregulation of nuclear factor--kappa B (NF-κB) activity where the Se status of the host may play a role in viral evolution, which has been associated with sepsis \[11,12\].

In plants and food, Se is mainly present as the amino acids selenomethionine and selenocysteine [@bib0013]. However, these organic forms of Se^2+^ are not available for intravenous supplementation. Thus, in the critical care setting Se has been mostly administered as inorganic selenite or selenious acid (Se^4+^) [@bib0010]. It is important to note that the conversion of Se^4+^ substrates to the element\'s divalent form (Se^+2^) facilitates oxidation of sulphydryl groups in protein disulphide isomerase (PDI), which plays an important role in viral pathogenesis and the spread of infection [@bib0014]. Thus, Se^+2^ shows oxidizing capacity reacting with thiol groups in the active site of viral PDI, converting them to inactive sulfhydryl groups. In this way, Se as selenite (Se^4+^) may be able to inhibit the entrance of SARS Cov-2 in host cells impeding its ability to infect healthy subjects [@bib0014].

It is well established that poor nutritional status of the host increases pathogenicity of viruses, increasing either susceptibility to illness or its severity in nutrient deficient animals [@bib0015]. According to the literature, several host nutritional factors have long been associated with an effect on a viral pathogen, specifically by altering its genome, which can impact the viral expression producing a new pathogenic viral phenotype [@bib0012]. Viral infection and Th1-related cytokines trigger the production of high amounts of ROS, and RNS due to the induction of inducible NO synthase enzyme [@bib0016]. Concomitantly, the synthesis of antioxidant selenoenzymes such as GPx-1, GPX3, and selenoprotein P (SELENOP) is downregulated in the infected cells. Thus, oxidative/nitrative stress and depletion of endogenous antioxidant levels enhance viral replication and the viral RNA mutation rate, inducing severe tissue damage in the infected host \[[@bib0012],[@bib0015], [@bib0016]\].

Over the las,t four decades, various studies have demonstrated the role of Se status as a determinant of viral virulence. An elegant Chinese mice study in 1980 showed that the lower the Se status, the higher the heart injury in coxsackievirus B4 infected animals [@bib0017]. Also, a benign strain of coxsackievirus B3 may become virulent and cause myocarditis in Se-deficient mice. Interestingly, Levander et al. [@bib0018] in another mouse model showed that Se deficiency increased the virulence of an already virulent strain of coxsackievirus B3 and Se deficiency was associated with the conversion of a non-virulent strain into virulent coxsackievirus with mutations in the viral genome.

In the early 1930s, clinical observations of juvenile cardiomyopathy by Chinese researchers during the outbreak of Keshan disease [@bib0018], found a higher incidence of the disease in Se deficient regions, as well as a protective and preventive effect of selenite supplementation. Clinicians also found a seasonal and annual variation, which suggested the presence of a viral agent \[[@bib0018],[@bib0019]\]. This suspicion was later confirmed by analysis of tissues from Keshan disease patients, which revealed the presence of coxsackieviruses. Similarly, Se deficiency has been demonstrated in other infections caused by RNA viruses that include common human pathogenic viruses influenza A, HIV, hepatitis C virus, Ebola virus, and potentially the novel coronavirus SARS-Cov 2 [@bib0012].

In addition to North East China, many other geographical regions, including parts of East Asia, Australasia, Europe, Africa, and South America have populations with low Se status, which mostly depends on Se content in soils \[[@bib0010],[@bib0012]\]. Increasing mortality has been associated with decreasing Se intakes [@bib0011]. Recently, in a retrospective Chinese study, Zhang et al. [@bib0020] analyzed data from the Baidu website. The authors looked for associations between regional or city mean hair Se content and recovery outcomes in Covid-19 patients. Through weighted linear regression models, the authors found a positive correlation between Se status and the cure rate, concluding that the higher the Se intake and Se status, the better the Covid-19 cure rate [@bib0020]. This constitutes the first report showing a higher SARS-Cov2 pathogenicity and mortality rate in Se deficient Chinese Covid-19 patients, but supports the results from an earlier volunteer study in UK [@bib0021] where the low Se status of subjects may have accelerated viral replication by down-regulating the immune response and increasing the permissiveness of the host for viral replication. These data could have implications for other RNA viruses, leading us to speculate that increasing GPx-3 activity with Se supplementation could improve immune function and downregulate systemic inflammation in Covid-19 patients.

Selenium Pharmaconutrition {#sec0004}
==========================

In critically ill patients with sepsis/septic shock we and others, have previously demonstrated an early reduction in serum/plasma Se levels due to capillary leakage [@bib0022]. SELENOP is the major selenoenzyme, accounting for up to 60% of plasma Se [@bib0011]. As critical illness is characterized by low plasma Se concentration, SELENOP decreases early in ICU patients with systemic inflammation and multiorgan failure. In 2009, this was demonstrated by Forceville et al. [@bib0023] who found that SELENOP decreases earlier than GPx-3 activity in those patients with sepsis and septic shock. Low Se status in sepsis negatively correlates with illness severity and when measured at ICU admission may be useful as an early predictor of ICU survival [@bib0022]. In this context, high-dose parenteral Se monotherapy has been extensively studied in different ICU patient populations and early results were encouraging [@bib0010]. The majority of randomized clinical trials (RCT) published between the late 1990s and 2015 reported that Se pharmaconutrition with intravenous Se 4^+^ as sodium selenite/selenious acid was well-tolerated, optimized Se status and enhanced activity of antioxidant selenoenzymes such as GPx and SELENOP [@bib0010]. These trials all demonstrated some improvement in clinical outcomes, such as overall mortality, reduced incidence of ventilator associated pneumonia (VAP) and infectious complications in the critically ill [@bib0010].

Everything changed in 2015, when the REDOXS study [@bib0024] of high dose glutamine dipeptide and antioxidants (including Se) concluded that antioxidant supplementation conferred no therapeutic benefit for the critically ill. The choice of patients and inappropriate 'off label' dosage of the dipeptide has been a common criticism of this study. Indeed, it could be postulated that an insufficient dose of Se or an ineffective dosing schedule may have been employed for the Se arms of the investigation. Furthermore, absence of an effect from Se pharmaconutrition might have been due to the fact that many patients were not Se depleted. North Americans mostly having having adequate Se status, in contrast to other populations which, as indicated earlier are frequently Se deficient \[[@bib0010],[@bib0011]\].

Subsequently, SISPCT [@bib0025], the German multicentre RCT of Se pharmaconutrition, compared high dose Se against procalcitonin (PCT) guided antimicrobial therapy in over 1000 patients with severe sepsis and septic shock. In this 2 × 2 factorial design, Bloos et al. [@bib0025] administered an initial bolus of 1000 µg (12.7 µmol) Se as selenite, followed by a daily infusion of 1000 µg (12.7 µmol) Se for 21 days or until ICU discharge but were unable to show any difference in 28-day mortality between the 4 patient groups. It is important to note that Se therapy did significantly shortened hospital length of stay (LOS) for sepsis patients by three days (26 vs. 29 days; p = 0.02) and there was a trend towards a reduction in ICU LOS (p=0.08).

This trial has a number of shortcomings. There was a markedly uneven distribution of patients, with for example, significantly more high risk sepsis patients requiring renal replacement therapy in the Se group. Inexplicitly, the mortalities observed (approx. 25% in all groups) were significantly lower than the 40% expected mortality in German ICUs [@bib0026], raising questions about the basic assumptions in the study protocol design. The intention to treat analysis also found a statistically significant interaction between Se and PCT, which had previously been reported [@bib0027]. This interaction adds further confusion to the results interpretation and is considered a major limitation of the study.

Pharmaconutrition and the Guidelines {#sec0005}
====================================

Notwithstanding any limitations, the large SISPCT trial [@bib0025] heavily influenced the most recent systematic review and meta-analysis on Se pharmaconutrition in the critically ill [@bib0028]. Aggregation of data from 14 Se monotherapy RCT and 7 RCT with Se and other antioxidants, failed to demonstrate any improvement in clinical outcomes8. In the latest guidelines from the European Society for Clinical Nutrition and Metabolism (ESPEN) [@bib0029], the Manzanares data [@bib0028] outweighs the previous meta-analysis published by Alhazzani et al [@bib0030] analysing 9 RCT and 792 septic patients, that had concluded high dose Se may reduce mortality. Singer et al. now recommend that antioxidants as high dose monotherapy should not be administered without proven deficiency [@bib0029].

On the other hand, the American Society of Parenteral and Enteral Nutrition (ASPEN) / Society of Critical Care Medicine (S.C.C.M) guidelines in 2016 [@bib0031] recommend the provision of a combination of antioxidant micronutrients "in safe doses" (i.e. 5-10 times DRI). The latest Canadian Critical Care Recommendations [@bib0032] also conclude that parenteral Se does not improve clinical outcomes, with the proviso that parenteral Se may be associated with a reduction in mechanical ventilator days. When the 4 studies investigating VAP were aggregated, Se supplementation is associated with a significant reduction in the occurrence of VAP (RR 0.69, 95% CI 0.55, 0.86, p=0.0008) [@bib0032].

The Hypothesis {#sec0006}
==============

With an appreciable level of disagreement between expert committees around the world, it is an opportune moment to pose the question**: Is intravenous Se therapy, as part of the therapeutic fight against acute respiratory failure in the ICU, worthy of re-investigation in Covid-19 patients?** Our affirmative answer and working hypothesis is: *"Early pharmacological interventions, including high-dose selenite pharmaconutrition could be effective at reducing the incidence and the progression from type 1 respiratory failure (non ARDS) to severe ARDS, multiorgan failure, and new infectious complications".* To test our hypothesis a comprehensive research program needs to address a number of issues and key questions by treating pharmaconutrients as drugs not as simple nutrients. Investigations need to be carried out on the pharmacokinetics (PK) and pharmacodynamics (PD) determining the optimum daily dosage (posology) based on BMI; evaluating any sex differences in metabolism; investigating any age-related influences on drug efficacy.

Selenium Pharmacokinetics (PK) and Pharmacodynamics (PD) {#sec0007}
========================================================

The first step will be to better understand the PK and PD involved and explore a potential link between plasma/serum Se, related antioxidant selenoenzymes, and the risk of catching SARS-Cov2 infection. Few studies have evaluated Se kinetic profiles in the critically ill. In healthy subjects, maximal activity of GPx-3 is achieved at a daily intake of 55-70 µg (0.70-0.89 µmol) Se and is associated with a plasma Se in the normal physiological range of 90-125 μg/L \[[@bib0033],[@bib0034]\]. Nonetheless, according to studies published between 1995 and 2003, in European countries serum or plasma Se levels in healthy adults shows a wide range from 50.22 to 145.29 μg/L [@bib0035]. However, critically ill, Se depleted ICU patients may require much higher doses. So far, intravenous sodium selenite or selenious acid is the most effective way to deliver a sufficiently high dose of Se for PK/PD investigations and to produce beneficial clinical effects in ICU patients. In a sheep model of sepsis, an initial i.v loading dose of sodium selenite 2000µg (25.3 μmol), produced an anti-inflammatory action that significantly reduced IL-6, and was associated with a significant improvement of hemodynamic parameters [@bib0036]. IL-6 is one of the most prominent cytokines upregulated during SARS-Cov2 infection [@bib0037]. Thus, in the early phase of Covid-19 disease, Se pharmaconutrition, following an initial loading dose, could regulate production of IL-6 and other cytokines, hence moderating ARDS, the most severe and frequent consequence of the cytokine storm. In 2010, our phase I dosing study [@bib0038], evaluating two different parenteral Se regimens, found that after an initial bolus injection of 1000μg Se, followed by continuous infusion of 1000µg (12.7 μmol) over 24 hours, the concentration-time curve showed that Se concentration does not normalize until day 10. Moreover the PD profile showed that maximum GPX3 activity was achieved at day 7, suggesting that high dose supplementation, somewhere between 100 µg (1.3 µmol) and 1000 µg /d (12.7 µmol/d) is required to optimize SELENOP, GPX3 and antioxidant status by increasing the bioavailability of reduced glutathione (GSH) [@bib0038].

Posology and BMI {#sec0008}
================

Further refinement in posology, based on bodyweight or body mass index (BMI), is necessary to eliminate an important variable, not considered in earlier studies. As we have previously indicated, in the Selenium in Intensive Care (SIC) study [@bib0039], the mean BMI was 27.1 +/- 8 kg/m^2^, but 10% of patients had low BMI (\<20 kg/m^2^) and 7.5% had a high BMI(\>40 kg/m^2^). Each patient received a fixed Se dose of approximately 1071 μg/d, which equates to a mean of 14 μg/kg/d, but those with the lowest BMI would have received approximately 19 μg/kg/d and those with high BMI only 11 g/kg/d, a significant 67% difference that might have affected outcome. Likewise, in SISPCT [@bib0025], the patients had a mean BMI of 28 +/- 7.5 kg/m^2^ i.e. some patients were approximately 70% heavier than others. Thus, providing a fixed daily Se dose to all patients meant that the actual amount of Se administered per kg of body weight could have varied significantly from one patient to another. Indeed, although patients in the Se intervention group received a mean daily infusion of 22 μg/kg/d Se, the actual individual dosage varied from 300 μg/d to 1352 μg/d. This equates to a 4-5 fold difference that could have influenced their response and outcome. In future studies the pharmaconutrient dose of Se, should be calculated from the patient\'s BMI.

Obesity {#sec0009}
=======

Evidence from Italy, where Covid-19 has been most virulent, suggests that overweight and obese patients have a higher risk of severe clinical symptoms during SARS-CoV-2 infection. Italians with obesity require more frequent hospitalization and admission for intensive care with assisted ventilation during SARS-CoV-2 related pneumonia, In a small study of 92 Covid-19 elderly (70.5±13.3 years) and predominantly male (61.9%) patients, Busetto et al. [@bib0040] report that overweight and obese patients, despite their younger age (67.0±12.6 years) were more likely to be admitted to ICU. Moreover, they had a higher need for non-invasive ventilation for pneumonia than normal weight patients aged 76.1±13.0 years, p\<0.01) [@bib0040]. Further support for our contention that any future pharmacological therapy should be administered on the basis of the weight and/or BMI of the patient.

Age and Sex {#sec0010}
===========

In the developed world more than 10% of the population is over 65 years with a male to female ratio of 0.75 and by 2030, one in five people will be classified as Old (75-84y) or Old Old (85y+). Classical drug PK take into consideration changes with Age in Adsorption, Distribution, Metabolism and Excretion "ADME" There are well established age-related physiological changes e.g. decreased lean body mass, decreased renal and hepatic flow, decreased cell-mediated immunity that can affect ADME of pharmaconutrients such as Se. Intracellular levels of various nutrients are known to vary between the young and the elderly, between male and females [@bib0041].

In Brazil, China, Iran and New Zealand there are both Se-rich regions and Se-poor regions. Consequently, patients from these regions, might have different 'normal' Se values. In the recent Brazilian investigation [@bib0042] almost half the subjects were \> 60 years with low Se intakes and Se status well below normal: males had a mean Se plasma concentration of 24.62±16.70 μg/L (median = 22.5 μg/L) and female levels were significantly lower 19.36±6.40 μg/L**2**. In contrast, mean hair Se levels in Enshi a Chinese city with a high recovery rate from Covid-19 [@bib0020] were 3.13 mg/kg in females compared to 2.21 mg/kg in males.

Similarly, in Iran healthy male serum levels at 102.2 ± 12 SD μg/L were also significantly higher than female levels of 93.9 ± 14 SD μg/L (p \<0.005), with a positive correlation between higher Se serum and age in men over 16y (P \< 0.001) [@bib0043].

How might these age and sex differences affect metabolic and clinical responses to supplementation? {#sec0011}
===================================================================================================

Under 'normal' conditions, the whole body half-life of L-selenomethionine is approximately 252 days, which is much longer than selenite half-life of 102 days \[[@bib0044],[@bib0045]\]. In Se- deficient male animals the reproductive organs assume greater importance, with the testes, epididymus and sperm taking up a high proportion of the administered Se dose [@bib0046]. Clearance from the body is slower and the elimination half-life is extended further. Conversely, Se-deficient females retain larger amounts of Se in all tissues, except the brain and reproductive organs [@bib0047]. Se is essential for spermatogenesis and is present in the capsule surrounding the sperm mitochondria. Consequently, Se status and supplementat efficacy is likely influenced by sex linked hormonal patterns, so that we should monitor Se status and ADME separately in both males and females after at least 2-3 months follow up in future supplementation studies [@bib0046].

In a sub group analysis of data from the REDOXS study, Heyland et al. [@bib0024] showed that antioxidant (Se) supplementation actually improved 28 day mortality for those under 65y but not for those older patients. Age and sex differences are not immediately obvious in the SISPCT [@bib0025] study where the mean age was 65y but the M:F ratio was 0.6 with over 4 fold differences in daily doses and according to the authors, age and the disease severity marker differed considerably between the study groups. Clearly age and sex differences have been an 'invisible' confounder in many pharmaconutrition studies. Now, in the Covid-19 era, it is surely not a coincidence that age and sex differences are increasingly being identified as important factors influencing the severity of the response to the virus.

Future Clinical Investigations {#sec0012}
==============================

Simultaneous to the new PK/PD studies, we propose that large-scale RCT aimed at addressing the questions of Age, Sex, BMI and optimum posology need to be designed. Groups of severely ill Covid-19 patients admitted to the ICU, will receive an initial loading dose of high dose iv sodium selenite, followed by Se monotherapy by parenteral route starting as soon as possible after admission to the ICU for up to 14 days with follow up on Se status and outcome measures for up to 100 days.

We believe there is sufficient evidence on the anti-inflammatory, immunological and antioxidant properties of Se that allows us to initiate further in depth investigations into metabolic and clinical aspects of Se pharmaconutrition as adjuvant therapy aimed at combating this global pandemic.
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